Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy

Internal Medicine Journal

Volumn 44, Issue 5, 2014, Pages 464-470

  Subramaniam, K ^a   Richardson, A ^a   Dodd, J ^a   Platten, J ^a   Shadbolt, B ^a   Pavli, P ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Clinical remission; Clinical response; Colectomy; Tumour necrosis factor alpha; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANAPHYLAXIS; ARTICLE; BRAIN ABSCESS; CHRONIC DISEASE; COLON RESECTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG RESISTANCE; MIDDLE AGED; OBSERVATIONAL STUDY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; UTILIZATION;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLECTOMY; COLITIS, ULCERATIVE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MESALAMINE; MIDDLE AGED; OBSERVATIONAL STUDY AS TOPIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899998067     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12397     Document Type: Article

References (22)

1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J etal. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
2. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf D etal. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265.
3. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J etal. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-1260.
4. Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G etal. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008; 2: 219-225.
5. Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N etal. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014; 146: 110-118.
6. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MGW etal. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910.
7. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C etal. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811.
8. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J etal. Ciclosporine versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomized controlled trial. Lancet 2012; 380: 1909-1915.
9. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-1629.
10. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048.
11. Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzén H, Tysk C, Järnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007; 102: 2513-2519.
12. Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N etal. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 2009; 29: 308-314.
13. García-Bosch O, Gisbert JP, Cañas-Ventura A, Merino O, Cabriada JL, Garcia-Sanchez V etal. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013; 7: 712-722.
14. Chowers Y, Sturm A, Sans M, Papadakis K, Gazouli M, Harbord M etal. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010; 4: 367-376.
15. Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S etal. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105: 2617-2625.
16. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH etal. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660-1666.
17. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB etal. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18: 201-211.
18. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S etal. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787.
19. Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32: 522-528.
20. Gisbert JP, González-Lama Y, Maté J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 19-37.
21. Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 2012; 47: 538-547.
22. Haritunians T, Taylor KD, Targan SR, Dubinsky M, Ippoliti A, Kwon S etal. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 2010; 16: 1830-1840.